Literature DB >> 10725953

von Hippel-Lindau disease.

V Couch1, N M Lindor, P S Karnes, V V Michels.   

Abstract

An autosomal dominant tumor predisposition syndrome, von Hippel-Lindau disease (VHL) is characterized by the presence of benign and malignant tumors. Hallmark lesions include retinal angiomas, hemangioblastomas of the cerebellum and spinal cord, and renal cell carcinomas. Affected persons may also have angiomatous or cystic lesions of the kidneys, pancreas, and epididymis, as well as adrenal pheochromocytomas. In this article, we discuss the clinical features and diagnostic criteria for this clinically underdiagnosed condition. An update on recent findings regarding the molecular genetics of VHL is provided, including a discussion of the evolving understanding of genotype-phenotype correlations. Understanding the molecular and functional aspects of this condition will lead to the development of strategies for the management and treatment of inherited and sporadic VHL-associated tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725953     DOI: 10.4065/75.3.265

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  20 in total

Review 1.  Hemangioblastomas of the lower spinal region: report of four cases with preoperative embolization and review of the literature.

Authors:  Alessandra Biondi; Giuseppe K Ricciardi; Tierry Faillot; Laurent Capelle; Rémy Van Effenterre; Jacques Chiras
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

Review 2.  Role of VHL gene mutation in human renal cell carcinoma.

Authors:  Wani Arjumand; Sarwat Sultana
Journal:  Tumour Biol       Date:  2011-11-29

Review 3.  Von Hippel-Lindau disease: a single gene, several hereditary tumors.

Authors:  J Crespigio; L C L Berbel; M A Dias; R F Berbel; S S Pereira; D Pignatelli; T L Mazzuco
Journal:  J Endocrinol Invest       Date:  2017-06-06       Impact factor: 4.256

Review 4.  Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors.

Authors:  Angela Trepanier; Mary Ahrens; Wendy McKinnon; June Peters; Jill Stopfer; Sherry Campbell Grumet; Susan Manley; Julie O Culver; Ronald Acton; Joy Larsen-Haidle; Lori Ann Correia; Robin Bennett; Barbara Pettersen; Terri Diamond Ferlita; Josephine Wagner Costalas; Katherine Hunt; Susan Donlon; Cecile Skrzynia; Carolyn Farrell; Faith Callif-Daley; Catherine Walsh Vockley
Journal:  J Genet Couns       Date:  2004-04       Impact factor: 2.537

Review 5.  Spinal cord and intradural-extraparenchymal spinal tumors: current best care practices and strategies.

Authors:  Andrew T Parsa; Janet Lee; Ian F Parney; Philip Weinstein; Paul C McCormick; Christopher Ames
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

6.  Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.

Authors:  A D Sorrell; S Lee; C Stolle; J Ellenhorn; A Grix; W G Kaelin; J N Weitzel
Journal:  Clin Genet       Date:  2011-06       Impact factor: 4.438

7.  A case of von Hippel-Lindau disease with exudative maculopathy.

Authors:  Basel T Ba Arah
Journal:  Oman J Ophthalmol       Date:  2009-05

Review 8.  Origin of renal cell carcinomas.

Authors:  Manuel Valladares Ayerbes; Guadalupe Aparicio Gallego; Silvia Díaz Prado; Paula Jiménez Fonseca; Rosario García Campelo; Luis Miguel Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

Review 9.  [Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].

Authors:  R Kuefer; M Autenrieth; K Herkommer; P Blum; A Merseburger; M Hofer; L Rinnab; J Gschwend; M Ringhoffer
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

10.  Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations.

Authors:  H-C Jennifer Shen; Asha Adem; Kris Ylaya; Arianne Wilson; Mei He; Dominique Lorang; Stephen M Hewitt; Klaus Pechhold; David M Harlan; Irina A Lubensky; Laura S Schmidt; W Marston Linehan; Steven K Libutti
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.